| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Adlai Nortye Ltd. American Depositary Shares$12.99
-0.01 (-0.08%)
C 54Pipeline Score Undervalued Biotech · Clinical
Market Cap
411.81 M
EPS
-
P/E Ratio
-
Value Trade
2.50 M
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
216.58 K
52 Week Range
0.88 - 12.15
% held by Insiders
9.36 %
% held by Institutions
24.26 %
Enterprise Value
414.40 M
Total Shares
31.24 M
Short %
11.31 %
Float Shares
28.02 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Adlai Nortye Ltd. American Depositary Shares
3Total events
1Upcoming
1Tier-1 (high impact)
2026 – 2027Coverage
Upcoming catalysts 1
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 2
TBD
▲First Patient DosedAN9025Trial
Subscribe to view catalyst details
TBD
▲Management ChangeCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-10-25 | AN4035 (CEACAM5-targeting antibody-drug conjugate) | Pre-clinical data readout | Pre-clinical | — | – | – | – |
2025-10-25 | AN4035 (CEACAM5-targeting antibody-drug conjugate) | Pre-clinical data readout | Pre-clinical | — | – | – | – |
2025-10-25 | AN4035 (CEACAM5-targeting antibody-drug conjugate) | Pre-clinical data readout | Pre-clinical | — | – | – | – |
Drug Pipeline Intelligence
C54
Pipeline Score $2.9B
Pipeline ValueUndervalued
Valuation Signal7
Drugs Scored7.1x
rNPV / MCap Top 84%
Micro Cap (rank 149 of 923)
Percentile RankAdlai Nortye Ltd. American Depositary Shares carries a moderate pipeline score (54/100), with $14.5B risk-adjusted pipeline value, led by AN2025 in Locally Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AN4005-dose level 0 Small molecule | Advanced Solid Tumor | Phase 1 | NCT04999384 | 5% | $4.2B | RECRUITING | 31 | STALLED | B (61) | Dec 1, 2026 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ANL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ANL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-ANL
Aug 3, 2026▼ -0.1%today
Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia
Adlai Nortye has received approval from Australia's HREC to begin a Phase I clinical trial for AN4035, a pan-RAS(ON) inhibitor ADC targeting CEACAM5. This trial aims to evaluate the drug's safety, tolerability, and efficacy in patients with specific solid tumors. The company is also preparing IND submissions to the FDA and NMPA.
Read more →-ANL
Jul 16, 2026▲ +6.8%on this news· ran to +22% by day 3
Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
Adlai Nortye has announced the dosing of the first patient in the intermittent weekly dosing arm of its Phase 1 trial for AN9025, a pan-RAS(ON) inhibitor. This approach aims to widen the therapeutic window, potentially improving tolerability and efficacy. Both the QD and QW arms are currently enrolling patients, with initial data expected in early 2027.
Read more →-ANL
Jul 13, 2026▼ -6.4%on this newsshared move
Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
Adlai Nortye Ltd. has expanded its Scientific Advisory Board by appointing Dr. David S. Hong and Dr. Piro Lito, both renowned oncologists. Their expertise in clinical development and RAS biology is expected to significantly influence the company's research and development strategies. This move underscores Adlai Nortye's commitment to advancing its innovative cancer therapies.
Read more →-ANL
Apr 16, 2026Adlai Nortye Announces $150.0 Million Private Placement Equity Financing
Adlai Nortye Ltd. has announced a private placement equity financing expected to raise approximately $150 million. The oversubscribed transaction involves participation from both new and existing institutional investors. The funds will support the development of the company's innovative cancer therapies, including RAS-targeting treatments. The private placement is set to close on April 17, 2026, pending customary conditions.
Read more →-ANL
Feb 12, 2026Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations
Adlai Nortye has initiated a Phase 1 clinical trial for AN9025, a pan-RAS inhibitor, with the first patient dosed in the U.S. This trial aims to assess the safety and efficacy of AN9025 in patients with solid tumors harboring RAS mutations. The study is part of a multi-regional collaboration with Jiangsu Aosaikang Pharmaceutical Co. Ltd.
Read more →-ANL
Feb 3, 2026Adlai Nortye Announces $140.0 Million Private Placement Equity Financing
Adlai Nortye Ltd. has announced a successful private placement equity financing, raising approximately $140 million. The financing involves the sale of Class A ordinary shares, co-led by Cormorant Asset Management and Columbia Threadneedle Investments. The funds will support the development of the company's innovative cancer therapies, particularly in RAS-targeting and next-generation immunotherapies.
Read more →-ANL
Dec 29, 2025▲ +9.8%on this news
Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China
Adlai Nortye has entered an exclusive licensing agreement with ASK Pharm for its pan-RAS (ON) inhibitor AN9025, granting ASK rights to develop and commercialize the drug in Greater China. The deal includes potential earnings of up to RMB 1.6 billion, with an upfront payment and milestone payments. This collaboration aims to accelerate the development of AN9025, which has shown promise in preclinical studies against RAS-mutant cancers.
Read more →-ANL
Oct 22, 2025ADLAI NORTYE LTD. c/o PO Box 309, Ugland House Grand Cayman, KY1-1104 Cayman Islands NOTICE OF 2025 EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To Be Held on
Adlai Nortye Ltd. has announced its extraordinary general meeting scheduled for December 1, 2025. Shareholders will be voting on several key proposals including a change of the company's domicile from the Cayman Islands to Singapore. The proposals also involve adopting a new charter and a change of the company's name. Shareholders of record as of October 30, 2025, will be eligible to participate in the voting process.
Read more →-ANL
Aug 8, 2024Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress - Company Announces Appointment of Roger Sawhney, M.D. as a New Member of the Board of Directors SINGAPORE and N
Adlai Nortye Ltd. reported its first half 2024 financial results, showcasing progress in its clinical pipeline and operational improvements. The company appointed Roger Sawhney, M.D. to its Board of Directors and shared promising data from its ongoing trials. Net loss for the period decreased significantly from the previous year, yet cash usage in operations remains a concern. The company is focused on the advancement of its lead candidate, buparlisib, with Phase 3 data expected in early 2025.
Read more →-ANL
May 23, 2024▼ -5.6%on this news· ran to -35% by day 3
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024 SINGAPORE and NORTH BRUNSWICK, N.J. and
Adlai Nortye Ltd. announced it will present findings on the combination of AN0025 and definitive chemoradiotherapy (dCRT) for treating unresectable locally advanced esophageal cancer at the ASCO 2024 meeting. The data highlights the potential efficacy observed in a previous clinical trial. AN0025, which acts as a selective EP4 inhibitor, may enhance treatment outcomes when combined with current chemotherapy techniques. The company continues to emphasize its commitment to innovative cancer therapies and global partnerships for advancing oncology research.
Read more →-ANL
Apr 2, 2024Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29 th , 2024 -- Adlai Nortye Ltd. (NASDAQ: ANL) (the "Company" or
Adlai Nortye Ltd. has announced the appointment of Dr. Archie Tse as the new Head of Research & Development. Dr. Tse, with an extensive background in oncology, previously held senior roles at CStone Pharmaceuticals, Merck, and Daiichi-Sankyo. His leadership is anticipated to strengthen the company's focus on developing innovative cancer therapies. Adlai Nortye aims to leverage Dr. Tse's expertise to enhance its R&D efforts and advance its pipeline of drug candidates.
Read more →Competitive Position
How ANL ranks across every disease it competes inCompetitive Position is a premium feature
See how ANL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial